ContributorsPublishersAdvertisers

KRd-ASCT Improves Long-Term PFS in Multiple Myeloma

targetedonc.com
 2021-10-03

Cover picture for the articlePromising survival results were shown in the FORTE trial of carfilzomib plus lenalidomide, and dexamethasone induction/consolidation with autologous stem cell transplant and maintenance with carfilzomib-lenalidomide in patients with multiple myeloma. Significantly prolonger progression-free survival survival (PFS) rates were observed for carfilzomib (Kyprolis)- lenalidomide (Revlimid)-dexamethasone induction/consolidation with autologous stem cell...

www.targetedonc.com

Comments / 0

Comments / 0